Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Core Viewpoint - Dyne Therapeutics, Inc. has successfully closed an upsized underwritten public offering, raising approximately $402.5 million to support its clinical programs targeting genetically driven neuromuscular diseases [1]. Group 1: Offering Details - The public offering consisted of 21,827,549 shares of common stock priced at $18.44 per share, including 2,847,071 shares from the underwriters' option to purchase additional shares [1]. - The offering was conducted under a shelf registration statement filed with the SEC on March 5, 2024, which became effective upon filing [3]. Group 2: Company Focus - Dyne Therapeutics is dedicated to improving the functionality of individuals with genetically driven neuromuscular diseases, developing therapeutics targeting muscle and the central nervous system [5]. - The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), along with preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease [5].